INOZYME PHARMA, INC.
321 Summer Street, Suite 400
Boston, MA 02210
August 19, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Inozyme Pharma, Inc. |
Registration Statement on Form S-3
File No. 333-258702
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Inozyme Pharma, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-258702), so that it may become effective at 4:30 p.m. Eastern time on August 23, 2021, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
| Very truly yours, | ||
| INOZYME PHARMA, INC. | ||
| By: | /s/ Axel Bolte | |
| Name: | Axel Bolte | |
| Title: | President and Chief Executive Officer | |
| cc: | Brian A. Johnson |
Wilmer Cutler Pickering Hale and Dorr LLP
